STU:LSI's PB Ratio is ranked better than 70.72% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs STU:LSI: 1.65
During the past 12 months, CK Life Sciences International Holdings's average Book Value Per Share Growth Rate was 7.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -3.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -5.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -1.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of CK Life Sciences International Holdings was 11.40% per year. The lowest was -9.40% per year. And the median was -0.30% per year.
Back to Basics: PB Ratio
CK Life Sciences International Holdings (STU:LSI) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
CK Life Sciences International Holdings PB Ratio Related Terms
CK Life Sciences International Holdings PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings PB Ratio Chart
CK Life Sciences International Holdings Annual Data
For the Biotechnology subindustry, CK Life Sciences International Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CK Life Sciences International Holdings PB Ratio vs Biotechnology Industry
CK Life Sciences International Holdings PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
CK Life Sciences International Holdings (STU:LSI) has a PB Ratio of 1.53 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CK Life Sciences International Holdings and its competitors. This is near median its historical median of 1.54. Over the past decade, CK Life Sciences International Holdings' PB Ratio has ranged from 0.73 to 2.74. According to the industry distribution chart, CK Life Sciences International Holdings ranks #361 out of 1233 companies in the Biotechnology industry, placing it in the top 29.3%.
Is CK Life Sciences International Holdings' PB Ratio too high?
CK Life Sciences International Holdings' current PB Ratio of 1.53 is near median its 10-year median of 1.54. Over the past 10 years, this metric has ranged from a low of 0.73 to a high of 2.74. The Biotechnology industry median PB Ratio is 2.83. CK Life Sciences International Holdings' value of 1.53 is 45.9% below this industry median. Based on the distribution chart, CK Life Sciences International Holdings ranks #361 out of 1233 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CK Life Sciences International Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CK Life Sciences International Holdings ranks #361 out of 1233 companies for PB Ratio. This puts CK Life Sciences International Holdings in the upper half of its industry. The industry median PB Ratio is 2.83. CK Life Sciences International Holdings' value of 1.53 is 45.9% below this benchmark. Historically, CK Life Sciences International Holdings' own PB Ratio has ranged from 0.73 to 2.74 over the past decade. While the company's 10-year median is 1.54 vs. the industry median of 2.83, CK Life Sciences International Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CK Life Sciences International Holdings's current PB Ratio of 1.53 is 45.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CK Life Sciences International Holdings and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CK Life Sciences International Holdings's current PB Ratio is 1.53, which is near median its own 10-year median of 1.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
CK Life Sciences International Holdings (STU:LSI) has a current PB Ratio of 1.53. The stock's GF Value™ is €0.08, compared to a current price of €0.07 — trading 17.5% below its estimated fair value. The current PB Ratio is 1.53, which is near median its 10-year median of 1.54 and 45.9% below the Biotechnology industry median of 2.83. CK Life Sciences International Holdings' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For CK Life Sciences International Holdings (STU:LSI), the current PB Ratio is 1.53 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CK Life Sciences International Holdings (STU:LSI) Overvalued in 2026?
Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued.
The current stock price of €0.07 is trading 17.5% below its estimated GF Value™ of €0.08.
Key valuation signals for STU:LSI:
PB Ratio: 1.53 (near median its 10-year median of 1.54)
GF Value™: €0.08 vs. price of €0.07 (17.5% below fair value)
Industry Position: 45.9% below the Biotechnology median (#361 of 1233)
No single metric tells the full story. See the STU:LSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CK Life Sciences International Holdings Business Description
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
34GF Score
Get the complete analysis for STU:LSI
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:LSI has been successfully added to your 
